HK1118079A1 - Cancer-rejection antigen peptide derived from glypican-3 (gpc3) for use in hla-a2-positive patient and pharmaceutical comprising the antigen - Google Patents

Cancer-rejection antigen peptide derived from glypican-3 (gpc3) for use in hla-a2-positive patient and pharmaceutical comprising the antigen

Info

Publication number
HK1118079A1
HK1118079A1 HK08109168.9A HK08109168A HK1118079A1 HK 1118079 A1 HK1118079 A1 HK 1118079A1 HK 08109168 A HK08109168 A HK 08109168A HK 1118079 A1 HK1118079 A1 HK 1118079A1
Authority
HK
Hong Kong
Prior art keywords
antigen
gpc3
glypican
hla
cancer
Prior art date
Application number
HK08109168.9A
Other languages
English (en)
Inventor
Yasuharu Nishimura
Tetsuya Nakatsura
Hiroyuki Komori
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of HK1118079A1 publication Critical patent/HK1118079A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK08109168.9A 2005-08-09 2008-08-18 Cancer-rejection antigen peptide derived from glypican-3 (gpc3) for use in hla-a2-positive patient and pharmaceutical comprising the antigen HK1118079A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005230702 2005-08-09
PCT/JP2006/315631 WO2007018199A1 (fr) 2005-08-09 2006-08-08 Peptide antigène dérivé du glypican-3 (gpc3) pour une utilisation chez des patients positifs à l’hal-a2 et produit pharmaceutique comprenant l’antigène

Publications (1)

Publication Number Publication Date
HK1118079A1 true HK1118079A1 (en) 2009-01-30

Family

ID=37727382

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08109168.9A HK1118079A1 (en) 2005-08-09 2008-08-18 Cancer-rejection antigen peptide derived from glypican-3 (gpc3) for use in hla-a2-positive patient and pharmaceutical comprising the antigen

Country Status (15)

Country Link
US (2) US8053556B2 (fr)
EP (1) EP1923463B1 (fr)
JP (1) JP5299942B2 (fr)
KR (1) KR101304243B1 (fr)
CN (3) CN104877008B (fr)
AU (1) AU2006277295B2 (fr)
BR (1) BRPI0614590A2 (fr)
CA (1) CA2619443C (fr)
ES (1) ES2373055T3 (fr)
HK (1) HK1118079A1 (fr)
IL (1) IL189389A (fr)
PL (1) PL1923463T3 (fr)
PT (1) PT1923463E (fr)
RU (1) RU2395519C2 (fr)
WO (1) WO2007018199A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101304243B1 (ko) 2005-08-09 2013-09-05 온코세라피 사이언스 가부시키가이샤 ＨＬＡ-Ａ2 양성 환자용 글리피칸-3(ｇｌｙｐｉｃａｎ-3)유래의 암 거절항원 펩티드 및 그를 포함하는 의약
CA2655361C (fr) 2006-06-16 2014-10-07 Kumamoto University Peptides antigeniques de rejet tumoral derives de la sparc, et medicaments qui les renferment
TWI438207B (zh) * 2007-02-21 2014-05-21 Oncotherapy Science Inc 表現腫瘤相關抗原之癌症的胜肽疫苗
US20130217122A1 (en) * 2012-02-21 2013-08-22 The Trustees Of The University Of Pennsylvania Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library
KR20140138900A (ko) 2012-03-09 2014-12-04 온코세라피 사이언스 가부시키가이샤 펩티드를 포함한 의약 조성물
EP2872653B1 (fr) * 2012-07-12 2019-03-13 Persimmune, Inc. Vaccins anticancéreux personnalisés et thérapies cellulaires immunitaires adoptives
ES2851123T1 (es) * 2014-09-26 2021-09-03 Baylor College Medicine Receptores quiméricos de antígeno específicos de glipicano-3 para inmunoterapia adoptiva
AU2015329070B2 (en) 2014-10-07 2018-11-22 Nec Corporation Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
TW201636358A (zh) * 2014-12-09 2016-10-16 腫瘤療法 科學股份有限公司 對於ｔｈ１細胞之ｇｐｃ３抗原決定位胜肽及含此之疫苗
ES2805829T3 (es) * 2015-03-09 2021-02-15 Cytlimic Inc Péptido derivado de GPC3, composición farmacéutica para el tratamiento o la prevención de cáncer usando el mismo, inductor de inmunidad y método para producir células presentadoras de antígeno
BR112017019776B1 (pt) 2015-03-18 2020-07-28 Omnicyte proteínas de fusão que compreendem glicoproteínas de superfície de alfavírus modificadas e antígeno associado a tumor e métodos dos mesmos
EP3281641B1 (fr) 2015-04-07 2020-12-16 Cytlimic Inc. Adjuvant pour les vaccins contre le cancer
CA2982034A1 (fr) * 2015-05-18 2016-11-24 Pieris Pharmaceuticals Gmbh Muteines de la lipocaline 2 humaine avec affinite pour glypican-3 (gpc3)
EP3527216B1 (fr) 2016-10-11 2024-02-14 NEC Corporation Médicament comprenant un agoniste du récepteur toll-like, la protéine lag-3, un dérivé du peptide hsp70 et un dérivé du peptide gpc3
JP2018093823A (ja) 2016-12-15 2018-06-21 Ｈｅａｒｔｓｅｅｄ株式会社 未分化幹細胞除去剤及び未分化幹細胞除去方法
CN106822861A (zh) * 2017-01-12 2017-06-13 中国人民解放军第二军医大学 抗原肽gpc3‑1和gpc3‑3在制备治疗肝癌药物中的应用
JP7131775B2 (ja) 2017-02-06 2022-09-06 国立研究開発法人国立がん研究センター 新規ｔ細胞受容体
WO2018195339A1 (fr) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Cellules immunitaires exprimant des récepteurs d'antigènes modifiés
CN108144071B (zh) * 2017-12-13 2021-05-18 中国医学科学院肿瘤医院 原发性肝癌磁共振双靶点特异性分子探针及其制备方法
WO2023224096A1 (fr) * 2022-05-18 2023-11-23 国立研究開発法人国立がん研究センター Vaccin contre le cancer utilisant un cocktail d'antigènes courants du cancer, un agent thérapeutique des cellules tcr/car-t, procédé de diagnostic compagnon et procédé de diagnostic du risque d'apparition du cancer par détection de cellules cancéreuses circulant dans le sang

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
CA2295321C (fr) * 1997-06-23 2008-01-29 Ludwig Institute For Cancer Research Nonapeptides et decapeptides isoles se fixant a des molecules hla, et leur utilisation
WO1999037764A2 (fr) * 1998-01-27 1999-07-29 Vlaams Interuniversitair Instituut Voor Biotechnologie Nouveaux membres de la famille des genes de glypicane
CA2395926A1 (fr) * 1999-12-28 2001-07-05 Curagen Corporation Acides nucleiques contenant des polymorphismes mononucleotidiques et procedes d'utilisation correspondants
CN1280307C (zh) * 2001-04-03 2006-10-18 宝生物工程株式会社 细胞毒性t淋巴细胞
WO2004022597A1 (fr) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Anticorps d'un peptide n-terminal du gpc3 solubilise dans le sang
JP4406607B2 (ja) * 2002-08-26 2010-02-03 オンコセラピー・サイエンス株式会社 ペプチド及びこれを含む医薬
AU2002330482A1 (en) * 2002-09-04 2004-03-29 Perseus Proteomics Inc. Method of diagnosing cancer by detecting gpc3
AU2003298786A1 (en) * 2002-11-26 2004-06-18 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2004067571A1 (fr) * 2003-01-30 2004-08-12 Wu, Mengchao Anticorps monoclonal contre l'hepatome humain et utilisation de celui-ci
JP4336898B2 (ja) 2003-10-29 2009-09-30 財団法人くまもとテクノ産業財団 悪性黒色腫（メラノーマ）の診断剤
JP4834839B2 (ja) 2004-10-19 2011-12-14 国立大学法人 熊本大学 悪性黒色腫（メラノーマ）の新規な診断キット
KR101304243B1 (ko) 2005-08-09 2013-09-05 온코세라피 사이언스 가부시키가이샤 ＨＬＡ-Ａ2 양성 환자용 글리피칸-3(ｇｌｙｐｉｃａｎ-3)유래의 암 거절항원 펩티드 및 그를 포함하는 의약
CA2655361C (fr) 2006-06-16 2014-10-07 Kumamoto University Peptides antigeniques de rejet tumoral derives de la sparc, et medicaments qui les renferment

Also Published As

Publication number Publication date
AU2006277295A1 (en) 2007-02-15
EP1923463A1 (fr) 2008-05-21
KR20080056153A (ko) 2008-06-20
CN101313063A (zh) 2008-11-26
CN101313063B (zh) 2013-04-03
CN104877008A (zh) 2015-09-02
PT1923463E (pt) 2011-11-24
CA2619443C (fr) 2014-07-08
CN104877008B (zh) 2018-06-05
IL189389A (en) 2011-11-30
US20090239806A1 (en) 2009-09-24
AU2006277295B2 (en) 2011-08-11
EP1923463A4 (fr) 2009-09-09
EP1923463B1 (fr) 2011-10-05
JPWO2007018199A1 (ja) 2009-02-19
ES2373055T3 (es) 2012-01-31
CN103242428A (zh) 2013-08-14
US20120040452A1 (en) 2012-02-16
BRPI0614590A2 (pt) 2013-05-14
IL189389A0 (en) 2008-06-05
US8535942B2 (en) 2013-09-17
RU2395519C2 (ru) 2010-07-27
CA2619443A1 (fr) 2007-02-15
US8053556B2 (en) 2011-11-08
KR101304243B1 (ko) 2013-09-05
WO2007018199A1 (fr) 2007-02-15
JP5299942B2 (ja) 2013-09-25
RU2008109015A (ru) 2009-09-20
CN103242428B (zh) 2015-04-15
PL1923463T3 (pl) 2012-02-29

Similar Documents

Publication Publication Date Title
HK1118079A1 (en) Cancer-rejection antigen peptide derived from glypican-3 (gpc3) for use in hla-a2-positive patient and pharmaceutical comprising the antigen
IL261346A (en) Tissue protective peptides and their uses
EP1751179A4 (fr) Peptides derives de la caseine et leurs utilisations therapeutiques
ZA200800464B (en) Peptides for use in the treatment of obesity
EP1951280A4 (fr) Peptides de techniques diagnostiques et therapeutiques de maladie coeliaque
EP1741783A4 (fr) Anticorps de beta peptide antiamyloïde humain et fragment anticorps de celui-ci
EP2102355A4 (fr) Protéines et peptides à action prolongée et procédés de production et d'utilisation de ces derniers
PL2010572T3 (pl) Białka fuzyjne zawierające polipeptydy HPV i peptydy wzmagające odporność do leczenia i zapobiegania rakowi szyjki macicy
PL2186889T3 (pl) Peptyd CDCA1 i środek farmaceutyczny go zawierający
EP1835027A4 (fr) Nouveau peptide antigène contre le cancer et applications
EP1893233A4 (fr) Peptides et vaccins thérapeutiques
IL188153A0 (en) Supravalent peptide compounds and processor for the preparation thereof
ZA200801874B (en) Antigenic peptides and their use
HK1209050A1 (en) Survivin-derived peptides and use thereof
GB0521490D0 (en) RFamide-related peptide precursor proteins and RFamide peptides
ZA200800566B (en) Therapeutic peptides and vaccines
GB0402129D0 (en) Therapeutic and diagnostic peptides
ZA200710374B (en) Pharmaceutical compositions comprising casein derived peptides and methods of use thereof
EP1910405A4 (fr) Peptides dérivés du complément c3a et utilisations de ceux-ci
GB0503093D0 (en) Ricin-binding peptide and methods for use thereof
IL177768A0 (en) Casein derived peptides and therapeutic uses thereof
GB0418156D0 (en) RFamide-related peptide precursor proteins and RFamide peptides
IL222485A (en) Medical preparations that contain peptide-derived peptides and methods for their use
IL187120A0 (en) Pharmaceutical compositions comprising casein derived peptides and methods of use thereof
EP1631309A4 (fr) Peptides de proteine kinase c utilises pour le sevrage